Issuers will hope the outperformance continues, as consensus is now that there will be no EPS growth in Q1. Bank of America ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

DIsney says it has sold out all commercial inventory for Sunday's Oscars, and notes packages include TV, streaming, social ...

PTC Therapeutics Inc (PTCT) surpasses revenue expectations, strengthens cash position, and prepares for multiple product ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

The FDA is mired in uncertainty with some staffers losing their jobs over the weekend and more potentially to come, vaccines ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Novartis AG (NYSE:NVS) had a strong Q4 2024, with net income soaring 26% to $3.93 billion, beating Wall Street’s expectations. The company now projects 5%+ sales growth until 2029. Novartis AG ...